melagatran

Melagatran is a synthetic, small-peptide direct thrombin inhibitor with anticoagulant activity. It acts as the active metabolite of ximelagatran, an oral prodrug that is rapidly converted to melagatran in vivo. Melagatran binds directly and competitively to the active site of thrombin, inhibiting both fluid-phase and clot-bound thrombin without requiring co-factors. This inhibition prevents the conversion of fibrinogen to fibrin and platelet activation, key steps in thrombosis formation. Melagatran was developed as an alternative to warfarin for indications such as prevention and treatment of deep vein thrombosis (DVT), stroke prevention in non-valvular atrial fibrillation, secondary prevention of recurrent venous thromboembolism after orthopedic surgery, and acute coronary syndromes. The drug has a rapid onset of action, short half-life (about 2–4 hours), low potential for drug interactions, stable absorption profile, and does not require routine monitoring or dose adjustment. However, its development was discontinued due to concerns about hepatotoxicity observed during clinical trials.